{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:25:44Z","timestamp":1785324344749,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinical-colorectal-cancer.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clcc.2024.06.002","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T23:00:58Z","timestamp":1718233258000},"page":"1-10.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chemotherapy Rechallenge or Reintroduction Compared to Regorafenib or Trifluridine\/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A Propensity Score Analysis of Treatment Beyond Second Line (Proserpyna Study)"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6856-2593","authenticated-orcid":false,"given":"M.A.","family":"Calegari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.V.","family":"Zurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dell'Aquila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Camarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Anghelone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sperduti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.C.","family":"Corsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2024.06.002_bib0001","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdx738","article-title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS","volume":"29","author":"Yoshino","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0002","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2024.06.002_bib0003","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2024.06.002_bib0004","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0005","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.clcc.2024.06.002_bib0006","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2024.06.002_bib0007","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.22915","article-title":"Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer","volume":"110","author":"Hecht","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2024.06.002_bib0008","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","article-title":"Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study","volume":"15","author":"Price","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0009","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","article-title":"Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial","volume":"5","author":"Cremolini","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0010","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","article-title":"Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial","volume":"28","author":"Sartore-Bianchi","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.clcc.2024.06.002_bib0011","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/annonc\/mdy038","article-title":"Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review","volume":"29","author":"Arnold","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0012","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0959-8049(99)00150-1","article-title":"CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR","volume":"35","author":"Andre","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2024.06.002_bib0013","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2017.06.029","volume":"83","author":"Cascinu","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2024.06.002_bib0014","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1200\/JCO.2004.03.119","article-title":"Randomized multicenter phase II trial of bolus plus infusional fluorouracil\/leucovorin compared with fluorouracil\/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer","volume":"22","author":"Kemeny","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0015","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s10147-015-0911-7","article-title":"Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (the ORION study)","volume":"21","author":"Matsuda","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0016","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.2147\/DDDT.S85567","article-title":"Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study","volume":"9","author":"Suenaga","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clcc.2024.06.002_bib0017","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/01.cad.0000127144.73043.57","article-title":"Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil","volume":"15","author":"Hartmann","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clcc.2024.06.002_bib0018","first-page":"5521","article-title":"Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer","volume":"32","author":"Yanai","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clcc.2024.06.002_bib0019","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2024.06.002_bib0020","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0021","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.21.02583","article-title":"Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, o(6)-methylguanine-DNA methyltransferase-silenced metastatic colorectal cancer: the MAYA trial","volume":"40","author":"Morano","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0022","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0023","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0024","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0025","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0026","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0027","doi-asserted-by":"crossref","first-page":"70","DOI":"10.7150\/jca.10478","article-title":"ERCC1 induction after oxaliplatin exposure may depend on KRAS mutational status in colorectal cancer cell line: in vitro veritas","volume":"6","author":"Orlandi","year":"2015","journal-title":"J Cancer"},{"key":"10.1016\/j.clcc.2024.06.002_bib0028","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00384-020-03571-5","article-title":"A systematic review of salvage therapies in refractory metastatic colorectal cancer","volume":"35","author":"Petrelli","year":"2020","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.clcc.2024.06.002_bib0029","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2024.06.002_bib0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1634\/theoncologist.2017-0275","article-title":"Propensity score analysis of regorafenib versus trifluridine\/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a japanese society for cancer of the colon and rectum multicenter observational study","volume":"23","author":"Moriwaki","year":"2018","journal-title":"Oncologist"},{"issue":"35","key":"10.1016\/j.clcc.2024.06.002_bib0031","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1200\/JCO.21.01993","article-title":"Transarterial radioembolization in patients with unresectable colorectal cancer liver metastases","volume":"39","author":"Lentz","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0032","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2024.06.002_bib0033","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2217\/fon-2020-1238","article-title":"Trifluridine\/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design","volume":"17","author":"Tabernero","year":"2021","journal-title":"Future Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002824000574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002824000574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T20:01:31Z","timestamp":1740254491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002824000574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1533002824000574"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2024.06.002","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy Rechallenge or Reintroduction Compared to Regorafenib or Trifluridine\/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A Propensity Score Analysis of Treatment Beyond Second Line (Proserpyna Study)","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2024.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}